• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Non-GMP Pilot Development Facility

Non-GMP Pilot Development Facility

Technology transfer from lab to market using the miniature version of glass cylindrical reactors.

Enabling pre-clinical program of NEW Chemical Entities (NCEs) and providing one stop solution to customize the product in rapid phase. The activities recorded in the electronic lab notebook enforces online documentation in accordance to principles of ALCOA+. Our value proposition: Discovery Research Quick access to the building blocks and key intermediates Time is essence of synthesis Enable the supply for discovery research 100g to few kilos
Early phase development Quick access to Drug substance for toxicology studies Phase appropriate PRD to enable the scale up Non GMP facility: Flexible operation and accelerated delivery

Speak to our experts

Infrastructure

  • 300+ fume hoods
  • Kilo lab with cylindrical reactor varying 5L to 50L capacity
  • Reactors from 500 L to 5000 L in Hyderabad & Bangalore
  • 50L autoclave a with 20kg/Cm2 design pressure
  • Pressure Nutsche filter, vaccum tray dryer and 20L rotavapor for downstream process
  • Huber unit to operate the process -20 to 150 degree Celsius
  • Internal network of strategic business partners
  • We also have a potent kilo lab

Scientific Expertise

  • Qualified PhDs and Postdocs in organic chemistry
  • 150+ scientists in chemistry and analytical services
  • 10+ process engineers and process safety engineers

Chemistry Capabilities

Expertise in

  • Metal promoted cross coupling reaction
  • Halogenation reactions
  • High pressure hydrogenation
  • Metal hydrate reactions
  • Carbohydrates
  • Lipids
  • Peptides
  • PEGylation
  • Asymmetric synthesis
  • Deuterated compound
  • Heterocyclic chemistry
  • Asymmetric hydrogenation
  • Chiral synthesis

Analytical Capability

  • High-performance liquid chromatography with varying detectors
  • Gas chromatography
  • Mass triple quad, 1H NMR Bruker
  • Differential scanning calorimeter
  • Micro calorimeter
  • Reaction calorimetry

Why Aurigene Pharmaceutical Services?

Quick turnaround of sample delivery

A strong scientific and analytical team

Infrastructure for mg to kg synthesis

Large network of qualified strategic business partners

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack